In this interview, Dr Joanna Osmanska (University of Glasgow, UK) outlines the findings of the SUBCUT-HF I (NCT04846816) and the SQI 01-01 studies (NCT04384653).
The studies, presented at Heart Failure 2022, demonstrated that the novel subcutaneous furosemide resulted in similar efficacy in terms of diuresis and natriuresis when compared to intravenous furosemide. In addition to this the subcutaneous administration of novel preparation of furosemide with custom-made patch pump was feasible and well tolerated by patients.
1. Importance of this Study
2. Investigational Product
3. Study Design and Eligibility Criteria
4. Key Findings
5. Take-Home Messages
6. Next Steps
Recorded on-site at Heart Failure 2022, Madrid.
Videographers: Tom Green & Mike Knight
Interviewer: Mirjam Boros